Wang Hongting, Lin Zuan-Tao, Yuan Yulin, Wu Tianfu
Department of Biomedical Engineering, University of Houston, Texas, United States of America; National Pharmacology Laboratory of Chinese Medicine, Basic Medical College. Wannan Medical College, Wuhu 241002, Anhui Province, China.
Department of Biomedical Engineering, University of Houston, Texas, United States of America.
J Transl Int Med. 2016 Sep 1;4(3):109-113. doi: 10.1515/jtim-2016-0032. Epub 2016 Sep 23.
There is a high risk for the survival of patients with an end-stage renal disease for kidney transplantation. To avoid rejection by strict medication adherence is of utmost importance to avoid the failure of a kidney transplant. It is imperative to develop non-invasive biomarkers to assess immunity risk, and to ultimately provide guidance for therapeutic decision-making following kidney transplantation. Urine biomarkers may represent the promising non-invasive tools that will help in predicting risk or success rates of kidney transplantations. Furthermore, composite urinary biomarkers or urinary biomarker panel array might be critical in improving the sensitivity and specificity in reflecting various risks of kidney failure during transplantation. This review primarily focuses on the role of such biomarkers in predicting chronic kidney disease (CKD) progression and/or cardiovascular disease (CVD) risk in renal allograft.
终末期肾病患者进行肾移植后生存面临高风险。通过严格坚持用药来避免排斥反应对于防止肾移植失败至关重要。开发非侵入性生物标志物以评估免疫风险并最终为肾移植后的治疗决策提供指导势在必行。尿液生物标志物可能是有前景的非侵入性工具,有助于预测肾移植的风险或成功率。此外,复合尿液生物标志物或尿液生物标志物面板阵列对于提高反映移植期间肾衰竭各种风险的敏感性和特异性可能至关重要。本综述主要关注此类生物标志物在预测肾移植受者慢性肾病(CKD)进展和/或心血管疾病(CVD)风险中的作用。